| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
692.40(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
57,878 |
165,115 |
165,115 |
195,533 |
| Total Sell Value |
$1,217,382 |
$3,085,988 |
$3,085,988 |
$4,069,195 |
| Total People Sold |
2 |
2 |
2 |
3 |
| Total Sell Transactions |
4 |
7 |
7 |
14 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vasista Vittal |
Chief Financial Officer |
• – – |
2020-05-11 |
4 |
AS |
$40.00 |
$20,000 |
D/D |
(500) |
206,715 |
|
-33% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-05-11 |
4 |
OE |
$13.09 |
$6,545 |
D/D |
500 |
207,215 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-05-08 |
4 |
AS |
$40.18 |
$281,260 |
D/D |
(7,000) |
206,715 |
|
-23% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-05-08 |
4 |
OE |
$13.09 |
$32,725 |
D/D |
2,500 |
213,715 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-04-24 |
4 |
AS |
$40.11 |
$481,320 |
D/D |
(12,000) |
211,215 |
|
-24% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-04-24 |
4 |
OE |
$13.09 |
$39,270 |
D/D |
3,000 |
223,215 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-04-23 |
4 |
AS |
$40.00 |
$120,000 |
D/D |
(3,000) |
220,215 |
|
-21% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-04-23 |
4 |
OE |
$13.09 |
$39,270 |
D/D |
3,000 |
223,215 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-03-31 |
4 |
OE |
$0.85 |
$8,500 |
D/D |
10,000 |
220,215 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-11 |
4 |
AS |
$50.13 |
$634,411 |
D/D |
(12,564) |
3,948 |
|
-27% |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-11 |
4 |
OE |
$22.00 |
$145,926 |
D/D |
6,633 |
16,512 |
|
- |
|
| Hayden Donald J Jr |
|
– • – |
2020-02-10 |
4 |
AS |
$50.11 |
$1,242,728 |
D/D |
(24,800) |
0 |
|
-25% |
|
| Hayden Donald J Jr |
|
– • – |
2020-02-10 |
4 |
OE |
$0.85 |
$21,080 |
D/D |
24,800 |
24,800 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-10 |
4 |
AS |
$50.22 |
$2,231,224 |
D/D |
(44,429) |
9,879 |
|
-25% |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-10 |
4 |
OE |
$19.50 |
$858,098 |
D/D |
31,660 |
54,308 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-02-10 |
4 |
AS |
$49.05 |
$741,352 |
D/D |
(14,806) |
210,215 |
|
-25% |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-02-10 |
4 |
OE |
$13.09 |
$39,270 |
D/D |
3,000 |
225,021 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-05 |
4 |
AS |
$50.00 |
$281,850 |
D/D |
(5,637) |
22,648 |
|
-23% |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2020-02-05 |
4 |
OE |
$13.09 |
$92,886 |
D/D |
5,137 |
28,285 |
|
- |
|
| Hayden Donald J Jr |
|
– • – |
2020-02-05 |
4 |
AS |
$50.00 |
$100,000 |
D/D |
(2,000) |
0 |
|
-23% |
|
| Hayden Donald J Jr |
|
– • – |
2020-02-05 |
4 |
OE |
$0.85 |
$1,700 |
D/D |
2,000 |
2,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-02-05 |
4 |
AS |
$50.00 |
$15,000 |
D/D |
(300) |
222,021 |
|
-23% |
|
| Hayden Donald J Jr |
|
– • – |
2020-01-14 |
4 |
AS |
$45.60 |
$1,368,000 |
D/D |
(30,000) |
0 |
|
-10% |
|
| Hayden Donald J Jr |
|
– • – |
2020-01-14 |
4 |
OE |
$0.85 |
$25,500 |
D/D |
30,000 |
30,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2020-01-08 |
4 |
AS |
$41.40 |
$313,152 |
D/D |
(7,500) |
224,715 |
|
-10% |
|
404 Records found
|
|
Page 7 of 17 |
|
|
0.30 (1.94%) 
